{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:06:31Z","timestamp":1790795191774,"version":"4.1.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interactions between the protein kinase C (PKC) and Chk1 inhibitor UCN-01 and the heat shock protein 90 (Hsp90) antagonist 17-AAG have been examined in human leukemia cells in relation to effects on signal transduction pathways and apoptosis. Simultaneous exposure (30 hours) of U937 monocytic leukemia cells to minimally toxic concentrations of 17-AAG (eg, 400 nM) and UCN-01 (eg, 75 nM) triggered a pronounced increase in mitochondrial injury (ie, loss of mitochondrial membrane potential [\u0394\u03c8m]; cytosolic release of cytochrome c), caspase activation, and apoptosis. Synergistic induction of apoptosis was also observed in other human leukemia cell types (eg, Jurkat, NB4). Coexposure of human leukemia cells to 17-AAG and the PKC inhibitor bisindolylmaleimide (GFX) did not result in enhanced lethality, arguing against the possibility that the PKC inhibitory actions of UCN-01 are responsible for synergistic interactions. The enhanced cytotoxicity of this combination was associated with diminished Akt activation and marked down-regulation of Raf-1, MEK1\/2, and mitogen-activated protein kinase (MAPK). Coadministration of 17-AAG and UCN-01 did not modify expression of Hsp90, Hsp27, phospho-JNK, or phospho-p38 MAPK, but was associated with further p34cdc2 dephosphorylation and diminished expression of Bcl-2, Mcl-1, and XIAP. In addition, inducible expression of both a constitutively active MEK1\/2 or myristolated Akt construct, which overcame inhibition of ERK and Akt activation, respectively, significantly attenuated 17-AAG\/UCN-01\u2013mediated lethality. Together, these findings indicate that the Hsp90 antagonist 17-AAG potentiates UCN-01 cytotoxicity in a variety of human leukemia cell types and suggest that interference with both the Akt and Raf-1\/MEK\/MAP kinase cytoprotective signaling pathways contribute to this phenomenon.<\/jats:p>","DOI":"10.1182\/blood-2002-12-3785","type":"journal-article","created":{"date-parts":[[2003,5,13]],"date-time":"2003-05-13T05:36:03Z","timestamp":1052804163000},"page":"1824-1832","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF\/MEK- and AKT-related pathways"],"prefix":"10.1182","volume":"102","author":[{"given":"Wentao","family":"Jia","sequence":"first","affiliation":[{"name":"From the Departments of Medicine, Biochemistry, Pharmacology, and Radiation Oncology, Virginia Commonwealth University, Medical College of Virginia, Richmond; and Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Yu","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Biochemistry, Pharmacology, and Radiation Oncology, Virginia Commonwealth University, Medical College of Virginia, Richmond; and Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rahmani","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Biochemistry, Pharmacology, and Radiation Oncology, Virginia Commonwealth University, Medical College of Virginia, Richmond; and Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Krystal","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Biochemistry, Pharmacology, and Radiation Oncology, Virginia Commonwealth University, Medical College of Virginia, Richmond; and Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Sausville","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Biochemistry, Pharmacology, and Radiation Oncology, Virginia Commonwealth University, Medical College of Virginia, Richmond; and Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dent","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Biochemistry, Pharmacology, and Radiation Oncology, Virginia Commonwealth University, Medical College of Virginia, Richmond; and Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Biochemistry, Pharmacology, and Radiation Oncology, Virginia Commonwealth University, Medical College of Virginia, Richmond; and Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021221295563900_REF1","doi-asserted-by":"crossref","unstructured":"Dunn FB. Heat shock protein inhibitor shows antitumor activity. J Natl Cancer Inst. 2002;94: 1194-1195.","DOI":"10.1093\/jnci\/94.16.1194"},{"key":"2020021221295563900_REF2","unstructured":"Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 2001;61: 4003-4009."},{"key":"2020021221295563900_REF3","doi-asserted-by":"crossref","unstructured":"Young JC, Moarefi I, Hartl FU. Hsp90: a specialized but essential protein-folding tool. J Cell Biol. 2001;154: 267-273","DOI":"10.1083\/jcb.200104079"},{"key":"2020021221295563900_REF4","unstructured":"Neckers L. Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treating hormonerefractory prostate cancer. Clin Cancer Res. 2002;8: 962-966."},{"key":"2020021221295563900_REF5","doi-asserted-by":"crossref","unstructured":"Blagosklonny MV. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia.2002;16: 455-462.","DOI":"10.1038\/sj.leu.2402415"},{"key":"2020021221295563900_REF6","doi-asserted-by":"crossref","unstructured":"Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13: 2905-2927.","DOI":"10.1101\/gad.13.22.2905"},{"key":"2020021221295563900_REF7","doi-asserted-by":"crossref","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2: 489-501.","DOI":"10.1038\/nrc839"},{"key":"2020021221295563900_REF8","doi-asserted-by":"crossref","unstructured":"Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91: 231-241.","DOI":"10.1016\/S0092-8674(00)80405-5"},{"key":"2020021221295563900_REF9","doi-asserted-by":"crossref","unstructured":"Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282: 1318-1321.","DOI":"10.1126\/science.282.5392.1318"},{"key":"2020021221295563900_REF10","doi-asserted-by":"crossref","unstructured":"Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Opin Cell Biol. 1997;9: 782-787.","DOI":"10.1016\/S0955-0674(97)80078-6"},{"key":"2020021221295563900_REF11","doi-asserted-by":"crossref","unstructured":"Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B\/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A. 1998;95: 11211-11216.","DOI":"10.1073\/pnas.95.19.11211"},{"key":"2020021221295563900_REF12","doi-asserted-by":"crossref","unstructured":"Kops GJ, Burgering BM. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med. 1999;77: 656-665.","DOI":"10.1007\/s001099900050"},{"key":"2020021221295563900_REF13","doi-asserted-by":"crossref","unstructured":"Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296: 1655-1657.","DOI":"10.1126\/science.296.5573.1655"},{"key":"2020021221295563900_REF14","unstructured":"Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3\u2032-kinase-AKT-dependent pathway. Cancer Res. 2002;62: 3132-3137."},{"key":"2020021221295563900_REF15","unstructured":"Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 1991;51: 4888-4892."},{"key":"2020021221295563900_REF16","unstructured":"Fuse E, Tanii H, Kurata N, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 1998;58: 3248-3253."},{"key":"2020021221295563900_REF17","doi-asserted-by":"crossref","unstructured":"Akinaga S, Nomura K, Gomi K, Okabe M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother Pharmacol. 1994;33: 273-280.","DOI":"10.1007\/BF00685899"},{"key":"2020021221295563900_REF18","doi-asserted-by":"crossref","unstructured":"Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem. 2000;275: 5600-5605.","DOI":"10.1074\/jbc.275.8.5600"},{"key":"2020021221295563900_REF19","doi-asserted-by":"crossref","unstructured":"Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996;88: 956-965.","DOI":"10.1093\/jnci\/88.14.956"},{"key":"2020021221295563900_","doi-asserted-by":"crossref","unstructured":"Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol. 1993;32: 183-189.","DOI":"10.1007\/BF00685833"},{"key":"2020021221295563900_REF21","unstructured":"Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res.2001;61: 1065-1072."},{"key":"2020021221295563900_REF22","unstructured":"Dai Y, Yu C, Singh V, et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase\/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001;61: 5106-5115."},{"key":"2020021221295563900_REF23","doi-asserted-by":"crossref","unstructured":"Qiao L, Yacoub A, McKinstry R, et al. Pharmacologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms. Cancer Biol Ther. 2002;1: 168-176.","DOI":"10.4161\/cbt.64"},{"key":"2020021221295563900_REF24","doi-asserted-by":"crossref","unstructured":"Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1\/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood. 2002;100: 3333-3343.","DOI":"10.1182\/blood-2002-03-0940"},{"key":"2020021221295563900_REF25","doi-asserted-by":"crossref","unstructured":"Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene. 2002;21: 1727-1738.","DOI":"10.1038\/sj.onc.1205225"},{"key":"2020021221295563900_REF26","unstructured":"Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3\u2032-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002;62: 1087-1092."},{"key":"2020021221295563900_REF27","unstructured":"Krystal GW, Sulanke, G, Litz J. Inhibition of PI3K-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther. 2002;1: 912-992."},{"key":"2020021221295563900_REF28","doi-asserted-by":"crossref","unstructured":"Nicholson KM, Anderson NG. The protein kinase B\/Akt signalling pathway in human malignancy. Cell Signal. 2002;14: 381-395.","DOI":"10.1016\/S0898-6568(01)00271-6"},{"key":"2020021221295563900_REF29","doi-asserted-by":"crossref","unstructured":"Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 2002;21: 1159-1166.","DOI":"10.1038\/sj.onc.1205184"},{"key":"2020021221295563900_REF30","doi-asserted-by":"crossref","unstructured":"Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase\/mitogen-activated protein kinase pathway. Mol Pharmacol. 2001;60: 143-154.","DOI":"10.1124\/mol.60.1.143"},{"key":"2020021221295563900_REF31","unstructured":"Wang Z, Van Tuyle G, Conrad D, Fisher PB, Dent P, Grant S. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis. Cancer Res. 1999;59: 1259-1267."},{"key":"2020021221295563900_REF32","doi-asserted-by":"crossref","unstructured":"Wang S, Vrana JA, Bartimole TM, et al. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-\u03b2-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol. 1997;52: 1000-1009.","DOI":"10.1124\/mol.52.6.1000"},{"key":"2020021221295563900_REF33","doi-asserted-by":"crossref","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22: 27-55.","DOI":"10.1016\/0065-2571(84)90007-4"},{"key":"2020021221295563900_REF34","doi-asserted-by":"crossref","unstructured":"Tafani M, Karpinich NO, Hurster KA, et al. Cytochrome c release upon Fas receptor activation depends on translocation of full-length bid and the induction of the mitochondrial permeability transition. J Biol Chem. 2002;277: 10073-10082.","DOI":"10.1074\/jbc.M111350200"},{"key":"2020021221295563900_REF35","doi-asserted-by":"crossref","unstructured":"Kim HR, Kang HS, Kim HD. Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life. 1999;48: 429-433.","DOI":"10.1080\/713803536"},{"key":"2020021221295563900_REF36","doi-asserted-by":"crossref","unstructured":"Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998;42: 273-279.","DOI":"10.1007\/s002800050817"},{"key":"2020021221295563900_REF37","doi-asserted-by":"crossref","unstructured":"Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem. 1999;74: 5053-5060.","DOI":"10.1074\/jbc.274.8.5053"},{"key":"2020021221295563900_REF38","doi-asserted-by":"crossref","unstructured":"Macdonald SG, Crews CM, Wu L, et al. Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro. Mol Cell Biol. 1993;13: 6615-6620.","DOI":"10.1128\/MCB.13.11.6615"},{"key":"2020021221295563900_REF39","doi-asserted-by":"crossref","unstructured":"Derijard B, Raingeaud J, Barrett T, et al. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science. 1995;267: 682-685.","DOI":"10.1126\/science.7839144"},{"key":"2020021221295563900_REF40","doi-asserted-by":"crossref","unstructured":"Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase\/Akt cell survival pathway. J Biol Chem. 1998;273: 19929-19932.","DOI":"10.1074\/jbc.273.32.19929"},{"key":"2020021221295563900_REF41","doi-asserted-by":"crossref","unstructured":"Widmann C, Gibson S, Johnson GL. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem. 1998;273: 7141-7147.","DOI":"10.1074\/jbc.273.12.7141"},{"key":"2020021221295563900_REF42","unstructured":"Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 1997;57: 4029-4035."},{"key":"2020021221295563900_REF43","unstructured":"Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res. 2001;7: 2228-2236."},{"key":"2020021221295563900_REF44","unstructured":"Yu C, Krystal G, Varticovksi L, et al. Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells. Cancer Res. 2002;62: 188-199."},{"key":"2020021221295563900_REF45","doi-asserted-by":"crossref","unstructured":"Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 2002;21: 5868-5876.","DOI":"10.1038\/sj.onc.1205724"},{"key":"2020021221295563900_REF46","doi-asserted-by":"crossref","unstructured":"Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100: 1068-1071.","DOI":"10.1182\/blood.V100.3.1068"},{"key":"2020021221295563900_REF47","unstructured":"Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2\/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002;8: 986-993."},{"key":"2020021221295563900_REF48","doi-asserted-by":"crossref","unstructured":"Yusta B, Estall J, Drucker DJ. Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem. 2002;277: 24896-24906.","DOI":"10.1074\/jbc.M201358200"},{"key":"2020021221295563900_REF49","doi-asserted-by":"crossref","unstructured":"An WG, Schnur RC, Neckers L, Blagosklonny MV. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol. 1997;40: 60-64.","DOI":"10.1007\/s002800050626"},{"key":"2020021221295563900_REF50","doi-asserted-by":"crossref","unstructured":"von Gise A, Lorenz P, Wellbrock C, et al. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol. 2001;21: 2324-2336.","DOI":"10.1128\/MCB.21.7.2324-2336.2001"},{"key":"2020021221295563900_REF51","doi-asserted-by":"crossref","unstructured":"Hipskind RA, Baccarini M, Nordheim A. Transient activation of RAF-1, MEK, and ERK2 coincides kinetically with ternary complex factor phosphorylation and immediate-early gene promoter activity in vivo. Mol Cell Biol. 1994;14: 6219-6231.","DOI":"10.1128\/MCB.14.9.6219"},{"key":"2020021221295563900_REF52","doi-asserted-by":"crossref","unstructured":"Troppmair J, Bruder JT, Munoz H, et al. Mitogen-activated protein kinase\/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J Biol Chem. 1994;269: 7030-7035.","DOI":"10.1016\/S0021-9258(17)37478-1"},{"key":"2020021221295563900_REF53","unstructured":"Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Unscheduled activation of cyclin B1\/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res. 1995;55: 228-231."},{"key":"2020021221295563900_REF54","doi-asserted-by":"crossref","unstructured":"Chauhan D, Hideshima T, Rosen S, Reed JC, Kharbanda S, Anderson KC. Apaf-1\/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2001;276: 24453-24456.","DOI":"10.1074\/jbc.C100074200"},{"key":"2020021221295563900_REF55","doi-asserted-by":"crossref","unstructured":"Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8: 705-711.","DOI":"10.1016\/S1097-2765(01)00320-3"},{"key":"2020021221295563900_REF56","doi-asserted-by":"crossref","unstructured":"Soderstrom TS, Poukkula M, Holmstrom TH, Heiskanen KM, Eriksson JE. Mitogen-activated protein kinase\/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J Immunol. 2002;169: 2851-2860.","DOI":"10.4049\/jimmunol.169.6.2851"},{"key":"2020021221295563900_REF57","unstructured":"Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res. 1994;54: 1707-1714."},{"key":"2020021221295563900_REF58","doi-asserted-by":"crossref","unstructured":"Toullec D, Pianetti P, Coste H, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991;266: 15771-15781.","DOI":"10.1016\/S0021-9258(18)98476-0"},{"key":"2020021221295563900_REF59","unstructured":"Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ. 1995;6: 927-936."},{"key":"2020021221295563900_REF60","doi-asserted-by":"crossref","unstructured":"Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol. 2001;19: 2319-2333.","DOI":"10.1200\/JCO.2001.19.8.2319"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/5\/1824\/1690697\/h81703001824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/5\/1824\/1690697\/h81703001824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T02:13:09Z","timestamp":1623031989000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/5\/1824\/17514\/Synergistic-antileukemic-interactions-between"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,1]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-12-3785","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,1]]}}}